Skip to content

The application of taVNS for neuroprotective therapy in patients with sepsis-associated encephalopathy

The application of taVNS for neuroprotective therapy in patients with sepsis-associated encephalopathy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118469
Enrollment
Unknown
Registered
2026-02-06
Start date
2026-02-06
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis-associated encephalopathy

Interventions

Sham stimulation group:Wear an ear stimulator, but do not give electrical stimulation

Sponsors

The Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria for sepsis-associated encephalopathy and the onset time is no more than 48 hours. 2. Age >= 18 years old. 3. The patient or his/her legal representative voluntarily participates in the study and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Local skin infections, deformities, traumas or post-operative scars on the ear, which affect the attachment of the electrodes; 2. Those who have had internal implantation of electronic medical devices such as cardiac pacemakers or defibrillators (ICD); 3. Those with a history of vagus nerve section or a clear history of cervical vagus nerve injury; 4. Those with a history of bradyarrhythmia (such as sinus arrest, high-grade atrioventricular conduction block) or who have experienced severe cardiovascular adverse events; 5. Those with known underlying central nervous system diseases (such as stroke, dementia, Parkinson's disease, epilepsy, etc.); 6. Those who have had a history of head trauma or neurosurgery within the last 3 months; 7. Those with end-stage diseases (expected survival time < 72 hours) or those receiving palliative treatment; 8. Those who are extremely agitated, have continuous epileptic seizures or are unable to maintain a resting state, which affects the implementation and evaluation of the intervention; 9. Pregnant women or lactating women; 10. Those who are participating in other intervention research clinical studies.

Design outcomes

Primary

MeasureTime frame
Protein S100 beta;Immunosuppressive molecules (CD4, CD8, regulatory T cells, etc.);

Secondary

MeasureTime frame
12 T-cell factors;Glasgow Coma Scale;Acute Physiology and Chronic Health Evaluation System;Sequential Organ Failure Assessment;Other inflammatory indicators ( PCT, etc.);Duration of mechanical ventilation;

Countries

China

Contacts

Public ContactZhang Linna

The Affiliated Hospital of Xuzhou Medical University

lindageshi0911@163.com+86 516 8580 6319

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026